BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15537904)

  • 21. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
    Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092
    [No Abstract]   [Full Text] [Related]  

  • 22. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?
    Hollander D
    Am J Gastroenterol; 2002 Aug; 97(8):1867-8. PubMed ID: 12190145
    [No Abstract]   [Full Text] [Related]  

  • 23. Summaries for patients. Treatment of Crohn disease with anti-tumor necrosis factor agent.
    Ann Intern Med; 2007 Jun; 146(12):I20. PubMed ID: 17470825
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
    Wittig BM; Zeitz M
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
    [No Abstract]   [Full Text] [Related]  

  • 25. Cytokine therapy for Crohn's disease: advances in translational research.
    Pizarro TT; Cominelli F
    Annu Rev Med; 2007; 58():433-44. PubMed ID: 17217333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor.
    Boscá MM; Pérez-Baylach CM; Solis MA; Antón R; Mayordomo E; Pons S; Mínguez M; Benages A
    Gut; 2006 Feb; 55(2):294-5. PubMed ID: 16407390
    [No Abstract]   [Full Text] [Related]  

  • 27. Cytokine-target therapies cost effective in Crohn's disease?
    McClellan K
    Drugs R D; 1999 Mar; 1(3):273-4. PubMed ID: 10566045
    [No Abstract]   [Full Text] [Related]  

  • 28. Natalizumab for active Crohn's disease.
    Lew EA; Stoffel EM
    N Engl J Med; 2003 Apr; 348(16):1599; author reply 1599. PubMed ID: 12700383
    [No Abstract]   [Full Text] [Related]  

  • 29. Crohn's disease: beyond antagonists of tumour necrosis factor.
    Peyrin-Biroulet L; Desreumaux P; Sandborn WJ; Colombel JF
    Lancet; 2008 Jul; 372(9632):67-81. PubMed ID: 18603161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Crohn's disease--the new era.
    Jewell DP
    Dig Liver Dis; 2002 Oct; 34(10):689-91. PubMed ID: 12469794
    [No Abstract]   [Full Text] [Related]  

  • 31. Biological response modifiers for the treatment of Crohn's disease.
    Siveke JT; Folwaczny C
    Expert Opin Biol Ther; 2004 Nov; 4(11):1719-27. PubMed ID: 15500400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: pro. Why use steroids if safer therapies are available?
    Baldassano RN
    Inflamm Bowel Dis; 2001 Nov; 7(4):338-41; discussion 345-6. PubMed ID: 11720326
    [No Abstract]   [Full Text] [Related]  

  • 33. Early combined immunosuppression in Crohn's disease.
    Danese S; Peyrin-Biroulet L
    Lancet; 2008 Jun; 371(9629):1996; author reply 1996-7. PubMed ID: 18555908
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-TNF antibody treatment of Crohn's disease.
    van Deventer SJ
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I114-20. PubMed ID: 10577987
    [No Abstract]   [Full Text] [Related]  

  • 35. Proinflammatory cytokines underlying the inflammation of Crohn's disease.
    Strober W; Zhang F; Kitani A; Fuss I; Fichtner-Feigl S
    Curr Opin Gastroenterol; 2010 Jul; 26(4):310-7. PubMed ID: 20473158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour necrosis factor and Crohn's disease.
    Van Deventer SJ
    Gut; 1997 Apr; 40(4):443-8. PubMed ID: 9176068
    [No Abstract]   [Full Text] [Related]  

  • 37. Oxpentifylline, tumour necrosis factor-alpha and Crohn's disease.
    MacDonald TT
    Gut; 1997 Apr; 40(4):559. PubMed ID: 9176092
    [No Abstract]   [Full Text] [Related]  

  • 38. Risankizumab for Induction and Maintenance of Remission in Crohn's Disease.
    Khanna R
    Gastroenterology; 2022 Nov; 163(5):1470-1471. PubMed ID: 35961380
    [No Abstract]   [Full Text] [Related]  

  • 39. Esophagogastric Crohn's Disease Manifested by Life-Threatening Odynophagia and Chest Pain: a Case Report.
    So H; Park BH; Jang K; Baek H; Kim YJ
    J Korean Med Sci; 2018 Jan; 33(4):e30. PubMed ID: 29318797
    [No Abstract]   [Full Text] [Related]  

  • 40. In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk.
    Oliver D; Talley NJ
    Ann Intern Med; 2022 Oct; 175(10):JC114. PubMed ID: 36191314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.